Company intelligence / Profile preview

KD Pharma Group

Bioggio, Ticino, Switzerlandkdpharmagroup.com ↗

Ownership: Private
Development stage: Phase 3

Overview

The company has commercialized highly purified Omega 3 APIs globally. It also runs late-stage clinical trials using lipid-based technologies targeting FAP, UC, and COVID 19. No detailed trial results are published in the provided sources.

Therapeutic areas: OtherGastroenterologyOncologyInfectious Diseases
Modalities: Small moleculeLipid-based therapy (notably Omega‑3 fatty acids)Softgel finished dosage forms
Industry: Biotech

Partnerships

Not specifically listed; works with global pharma/nutritional companies as CDMO partner.

Beyond the preview

Go deeper on KD Pharma Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KD Pharma Group.

Explore the full profile